[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, Cohn DE, Ioffe OB: A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol; 2007 Nov;107(2):177-85
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
  • PURPOSE: After initial surgery, there has been no established consensus regarding adjunctive therapy for patients with uterine carcinosarcoma (CS).
  • This study was designed to compare patient outcome following treatment with adjuvant whole abdominal irradiation (WAI) versus (vs.) chemotherapy for patients with this rare group of female pelvic malignancies.
  • PATIENTS AND METHODS: Eligible, consenting women with stage I-IV uterine CS, no more than 1 cm postsurgical residuum and/or no extra-abdominal spread had their treatments randomly assigned as either WAI or three cycles of cisplatin (C), ifosfamide (I), and mesna (M).
  • FIGO stage (both arms) was: I=64 (31%); II=26 (13%); III=92 (45%); IV=24 (12%).
  • Adjusting for stage and age, the recurrence rate was 21% lower for CIM patients than for WAI patients (relative hazard [RH]=0.789, 95% confidence interval [CI]: (0.530-1.176), p=0.245, 2-tail test).
  • CONCLUSION: We did not find a statistically significant advantage in recurrence rate or survival for adjuvant CIM over WAI in patients with uterine CS.
  • However, the observed differences favor the use of combination chemotherapy in future trials.

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):687-90 [12445244.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(5):352-7 [11766739.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):786-96 [14967435.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):204-8 [15047237.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):191-6 [15262141.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Dec;12(12):2127-30 [3793549.001]
  • [Cites] Stat Med. 1992 Apr;11(6):813-29 [1594819.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] Gynecol Oncol. 1994 Jan;52(1):56-62 [8307502.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):493-8 [9190981.001]
  • [Cites] Gynecol Oncol. 1998 Jan;68(1):8-13 [9454652.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(6):541-6 [10215437.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):232-7 [10021306.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):389-95 [10366465.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):630-4 [15721404.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):166-70 [15790453.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):295-300 [15923804.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):526-31 [17290061.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):808-18 [18378136.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):147-53 [11063636.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):282-5 [11373106.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(3):194-200 [11501770.001]
  • [CommentIn] Gynecol Oncol. 2007 Nov;107(2):166-8 [17950382.001]
  • (PMID = 17822748.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517-15; United States / NCI NIH HHS / CA / CA27469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA37517; United States / NCI NIH HHS / CA / U10 CA027469-19
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protective Agents; NR7O1405Q9 / Mesna; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Other-IDs] NLM/ NIHMS33375; NLM/ PMC2752331
  •  go-up   go-down


2. Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, Miller BE, Susumu N, Ueland FR: Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol; 2010 Jun 01;28(16):2727-31
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
  • PURPOSE: Platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor).
  • Ifosfamide plus paclitaxel is the regimen with established superiority based on a randomized phase III trial conducted through the Gynecologic Oncology Group.
  • Our primary objective was to estimate the antitumor activity and toxicity of paclitaxel plus carboplatin in patients with uterine carcinosarcomas.
  • PATIENTS AND METHODS: Eligible patients had advanced stage (III or IV), persistent or recurrent measurable disease, and no prior chemotherapy.
  • Patients received paclitaxel at 175 mg/m(2) intravenously (IV) over 3 hours plus carboplatin (area under the serum concentration-time curve = 6) IV over 30 minutes every 3 weeks until disease progression or until adverse effects occurred.
  • Treatment was well tolerated with expected hematologic toxicity and minimal nonhematologic grade 4 toxicity (one cardiovascular and two pain) with 59% of patients completing six or more cycles of chemotherapy.
  • CONCLUSION: Paclitaxel plus carboplatin demonstrates antitumor activity against uterine carcinosarcoma with acceptable toxicity and warrants further evaluation in phase III randomized trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinosarcoma / drug therapy. Carcinosarcoma / mortality. Uterine Neoplasms / drug therapy. Uterine Neoplasms / mortality
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Carboplatin / administration & dosage. Carboplatin / adverse effects. Confidence Intervals. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Immunohistochemistry. Infusions, Intravenous. Kaplan-Meier Estimate. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Probability. Prognosis. Program Evaluation. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1962-6 [1941054.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):70-5 [9345359.001]
  • [Cites] Am J Clin Oncol. 1998 Jun;21(3):306-7 [9626805.001]
  • [Cites] Stat Med. 1998 Oct 30;17(20):2301-12 [9819829.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):526-31 [17290061.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):177-85 [17822748.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):58-62 [17935761.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):147-53 [11063636.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):268-70 [11606082.001]
  • [Cites] Gynecol Oncol. 2002 May;85(2):311-4 [11972393.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):774-8 [15350372.001]
  • [Cites] Ann Intern Med. 1973 Oct;79(4):604-5 [4748282.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1648-53 [3884128.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Am J Clin Oncol. 1985 Oct;8(5):350-2 [3840643.001]
  • [Cites] Biometrics. 1985 Sep;41(3):741-4 [4074823.001]
  • [Cites] Cancer Treat Rep. 1986 Feb;70(2):271-4 [3948191.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):618-21 [3559652.001]
  • [Cites] Cancer Treat Rep. 1987 Jun;71(6):661-2 [3034423.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):935-8 [2914299.001]
  • [Cites] Am J Obstet Gynecol. 1989 Aug;161(2):309-12 [2548382.001]
  • [Cites] Gynecol Oncol. 1989 Sep;34(3):372-8 [2548936.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):32-4 [2154921.001]
  • [Cites] Semin Oncol. 1990 Apr;17(2 Suppl 4):6-10 [2159188.001]
  • [Cites] Invest New Drugs. 1991 Feb;9(1):93-4 [2026490.001]
  • [Cites] Am J Clin Oncol. 1996 Aug;19(4):400-2 [8677914.001]
  • (PMID = 20421537.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2881851
  •  go-up   go-down


3. Nassar OA, Abdul Moaty SB, Khalil el-SA, El-Taher MM, El Najjar M: Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results. J Egypt Natl Canc Inst; 2010 Jun;22(2):113-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results.
  • PURPOSE: Uterine corpus sarcomas are rare heterogeneous tumors characterized by rapid progression and poor response to treatment.
  • This series investigated treatment options, relapse pattern, survival and prognostic factors.
  • PATIENTS AND METHODS: A total of 59 patients were treated in the National Cancer Institute, Cairo University, (2000-2007).
  • Leiomyosarcoma accounted for 42.2% followed by carcinosarcoma (35.5%) and endometrial stromal sarcoma (18.6%).
  • 40.7% had FIGO stage I disease, 30.5% were II, 16.9% were III and 11.9% were IV.
  • Surgery was the primary line of treatment for all cases with total abdominal hysterectomy and bilateral salpingoophorectomy in 88% of cases and 12% had less extensive surgery.
  • Twenty-four (40.7%) patients had surgery alone, 24 (40.7%) had surgery and radiotherapy, 7 (11.9%) had surgery and chemo-irradiation and 4 (6.7%) had surgery and chemotherapy.
  • Stage, adjuvant irradiation, tumor size, myometrial invasion, vascular and cervix invasion were significant factors in univariate analysis; nevertheless, multivariate prognostic factors were only stage (p=0.04) and adjuvant irradiation (p=0.01).
  • 5-year cumulative disease free survival for stage I was 63.6%, 41.2% for stage II, 10% for stage III and 0% in stage IV.
  • Neither extent of surgery, chemotherapy, histologic type or grade had significant effect on survival.
  • Adjuvant radiotherapy offered 62% 2-year cumulative overall survival versus 22% for surgery alone and surgery with chemotherapy.
  • CONCLUSION: Diagnosis of uterine sarcoma is in itself a poor prognostic factor.
  • Complete cytoreductive surgery and adjuvant radiotherapy is essential for local control, provided tumor is limited to the uterus.
  • KEY WORDS: Uterine cancer - Uterine sarcoma - Uterine sarcoma treatment - Sarcoma irradiation - Sarcoma prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21860468.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


Advertisement
4. Wong L, See HT, Khoo-Tan HS, Low JS, Ng WT, Low JJ: Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed müllerian tumors of the uterus. Int J Gynecol Cancer; 2006 May-Jun;16(3):1364-9
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed müllerian tumors of the uterus.
  • The role of adjuvant therapy for malignant mixed müllerian tumors of the uterus has not been established.
  • Our aim was to review our experience with sequential adjuvant therapy using cisplatin and ifosfamide chemotherapy and radiotherapy after surgical staging.
  • The Cox proportional hazard regression model was used to assess the effect of treatment on survival after adjustment for age and stage.
  • Twenty-eight patients received adjuvant chemotherapy and 28 patients had adjuvant radiotherapy.
  • Twenty-one patients underwent sequential adjuvant chemotherapy and radiotherapy.
  • The 2- and 5-year survival for stage I and II diseases was both 95%, while the 2-year survival for stage III and IV diseases was 25%.
  • Patients who underwent sequential adjuvant therapy had an improved survival compared with patients who did not follow the protocol (P= 0.024).
  • Our results with sequential adjuvant therapy are encouraging and justify future randomized trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Ifosfamide / administration & dosage. Mixed Tumor, Mullerian / drug therapy. Mixed Tumor, Mullerian / radiotherapy. Uterine Neoplasms / drug therapy. Uterine Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy / statistics & numerical data. Disease-Free Survival. Drug Evaluation. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Postoperative Period. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803531.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


5. Mundhenke C, Bauerschlag D, Fischer D, Friedrich M, Maass N: [Malignant tumors of the uterus]. Ther Umsch; 2007 Jul;64(7):381-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant tumors of the uterus].
  • [Transliterated title] Maligne Tumoren des Uterus.
  • Malignant uterine tumors are responsible for up to 9% of all new cancer cases and for 4.5% of all cancer related deaths in women.
  • The three important uterine cancers are endometrial cancers, uterine sarcomas and cervical cancers.
  • Endometrial cancers are typically found in elderly women and are > 70% hormone sensitive (type I), type II is often less differentiated and not hormone sensitive.
  • Diagnosis can be achieved by vaginal ultrasound and by histology after hysteroscopy and curettage of the uterine cavity.
  • Therapy of choice is the stage related radical hysterectomy (incl. lymphnode dissection).
  • Postoperatively and at progressive stages endocrine and radiation therapies can be useful.
  • Chemotherapy is only useful in not hormone sensitive and in progressive tumors.
  • Uterine sarcomas are a rare and heterogeneous group of tumors.
  • These often aggressive tumors are hardly responding to systemic and radiation therapy.
  • Therefore radical tumor surgery plays the main therapeutic role.
  • In early stages a radical hysterectomy (incl. pelvine (+paraaortal) lymphonodectomy) and in rare cases an uterus preserving surgery should be performed.
  • [MeSH-major] Sarcoma. Uterine Neoplasms
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cervix Uteri / pathology. Combined Modality Therapy. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / epidemiology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Endometrium / pathology. Female. Humans. Hysterectomy. Hysteroscopy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Postoperative Care. Risk Factors. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948755.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 36
  •  go-up   go-down


6. Hiura M, Nogawa T, Matsumoto T, Yokoyama T, Shiroyama Y, Wroblewski J: Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma. Int J Gynecol Cancer; 2010 Aug;20(6):1000-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
  • OBJECTIVE: The purposes of this study were to assess modified radical hysterectomy including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy in patients with para-aortic lymph node (PAN) metastasis in endometrial carcinoma and to identify the multivariate independent prognostic factors for long-term survival during the past 10 years.
  • METHODS: Between December 1987 and December 2002, we performed modified radical hysterectomy with bilateral salpingo-oophorectomy including systematic pelvic and para-aortic lymphadenectomy and peritoneal cytology in 284 endometrial carcinoma patients according to the classification of the International Federation of Gynecology and Obstetrics (stage IA, n = 66; stage IB, n = 96; stage IC, n = 33; stage IIA, n = 5; stage IIB, n = 20; stage IIIA, n = 28; stage IIIC, n = 28; and stage IV, n = 8) who gave informed consents at our institute.
  • Patients with tumor confined to the uterus (stages IC and II) were treated by 3 courses of cyclophosphamide 750 mg/m2, epirubicin 50 mg/m2, and cisplatin 75 mg/m2 regimen 3 to 4 weeks apart, and patients with extrauterine lesions involving adnexa and/or pelvic lymph node (PLN) were treated by 5 courses.
  • Patients with PLN metastasis received adjuvant chemotherapy, and adjuvant radiation was not part of our institutional protocol.
  • RESULTS: The overall incidence of retroperitoneal lymph node metastasis assessed by systematic pelvic and para-aortic lymphadenectomy was 12.0% (34/284) in stages I to IV endometrial carcinoma, and incidences of PLN and PAN metastases were 9.2% (26/284) and 7.4% (21/284), respectively.
  • Univariate analysis of prognostic factors revealed that International Federation of Gynecology and Obstetrics clinical stage (P < 0.0001), histological finding (P = 0.0292), myometrial invasion (P < 0.0001), adnexal metastasis (P < 0.0001), lymphovascular space invasion (P < 0.0001), tumor diameter (P = 0.0108), peritoneal cytology (P = 0.0001), and retroperitoneal lymph node metastasis (P < 0.0001) were significantly associated with 10-year overall survival.
  • CONCLUSIONS: It is suggested that surgery with systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy could improve long-term survival in patients with PAN metastasis, although there are only 21 patients with PAN metastasis.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / secondary. Chemotherapy, Adjuvant. Endometrial Neoplasms / mortality. Endometrial Neoplasms / therapy. Retroperitoneal Neoplasms / secondary. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Aorta, Abdominal. Biopsy, Needle. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Lymph Node Excision / methods. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Retroperitoneal Space. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683408.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Yamamoto G, Shimada T, Nishida T, Ishida Y, Iba T, Nakata T, Ohtsuki T, Takigami K, Yamaguchi Y, Yoshitake K, Tanaka A, Tsuda Y: [Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers]. Gan To Kagaku Ryoho; 2001 Aug;28(8):1111-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers].
  • Nedaplatin (cis-diammine-glycolato platinum: CDGP) is a platinum compound with a molecular weight of 303.18 that was recently developed in Japan.
  • There have been reports of the antineoplastic effects of Nedaplatin on cancers in the cranio-cervical region, lung, esophagus, urinary bladder, testis, ovary, and uterus.
  • In this study, we performed combined therapy of CDGP and fluorouracil (5-FU) for 8 patients with oral cancers, and evaluated the results to elucidate the clinical effect and adverse side effects.
  • The subjects were 8 patients with squamous cell carcinoma (5 males and 3 females aged 33-65 years).
  • The primary carcinoma regions were the tongue in 5 patients, oral floor in 2 patients, and mandibular gingiva in 1 patient.
  • The T-classification was T2 in 6 patients and T4 in 2 patients, and the clinical staging was Stage II in 5 patients, Stage III in 1 patient and Stage IV in 2 patients.
  • The adverse side effects were slight myelotoxicity, gagging, nausea, alopecia, and stomatitis less than Grade II.
  • Although the oral cancers in this study were extroverted superficial ulcerative cancers, and the number of patients was low at 8, this combined therapy is considered useful and worth evaluating in further accumulated cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Remission Induction

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11525027.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Kodama J, Seki N, Ojima Y, Nakamura K, Hongo A, Hiramatsu Y: Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus. Eur J Obstet Gynecol Reprod Biol; 2007 Mar;131(1):76-80
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus.
  • OBJECTIVE: The purpose of this study was to determine the value of prognostic factors and to assess the efficacy of adjuvant chemotherapy in patients with endometrial cancer confined to the uterus.
  • STUDY DESIGN: Patients surgically stage IB, IC and II endometrial cancer according to the International Federation of Gynecology and Obstetrics were enrolled in this study.
  • Stage IIIA tumors with positive peritoneal cytology, in the absence of other evidence of extra uterine disease, were also included.
  • RESULTS: One hundred and sixty-seven patients fulfilled the eligibility criteria and 58 patients (34.7%) underwent combination chemotherapy.
  • Disease recurrence occurred in 10 patients within a median time of 17 months.
  • Fourteen of 23 patients with histologic grade 3 tumors received adjuvant chemotherapy consisting of cyclophosphamide (or etoposide), epirubicin and cisplatin (in 1989-1999) or paclitaxel, pirarubicin and carboplatin (in 2000-2002).
  • The 5-year disease-free and overall survival rates for these individuals was 92.3%, a value significantly higher than those in patients who had not undergone chemotherapy (50.0%).
  • CONCLUSIONS: Histologic grade of 3 is an independent prognostic marker in patients with endometrial cancer confined to the uterus and adjuvant chemotherapy might improve the survival rates in these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Treatment Outcome. Uterus / pathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459012.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Macchia G, Ferrandina G, Legge F, Deodato F, Ruggieri V, Lorusso D, Padula GD, Valentini V, Cellini N, Scambia G, Morganti AG: Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase II study (ESTER-1). Am J Clin Oncol; 2010 Dec;33(6):577-82
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase II study (ESTER-1).
  • INTRODUCTION: The aim of this phase II study was to evaluate response and toxicity of a prolonged chemoradiation regimen in patients with locally advanced cervical cancer.
  • PATIENTS AND METHODS: Three cycles of concomitant chemotherapy were used with cisplatin (20 mg/m², 2-hour intravenous infusion, days 1-4) and 5-fluorouracil (1000 mg/m², 24-hour continuous intravenous infusion, days 1-4) administered at weeks 1, 5, and 9 of radiotherapy.
  • The CTV was defined as follows: gross tumor volume, upper half of the vagina (if not involved) or the whole vagina (if clinically involved), uterus, obturator nodes, external iliac nodes, internal iliac nodes, and the presacral nodes (cranial to S2).
  • The prescribed dose to the PTV was 50 Gy, 2 Gy/fraction (ICRU 62) delivered in 25 fractions with a 2-week break at 20Gy and 40 Gy (split-course technique).
  • Clinical stage was: IB2-II: 19 patients (76%), III-IVA: 6 patients (24%).
  • All patients completed the prescribed dose of chemoradiation and were evaluated 4 weeks after the end of treatment.
  • About 32% of patients experienced grade 3 to 4 toxicity, in particular, grade 3 or 4 hematological toxicity was observed in 7 patients and 1 patient developed grade 3 genitourinary toxicity.
  • No patients developed grade 3 gastrointestinal toxicity or skin toxicity.
  • Seven patients (28%) showed a complete response (CR) to treatment, and 7 patients (28%) showed microscopic residual disease (μPR), totaling 14 patients (56%) complete/partial microscopic responses.
  • Perioperative morbidity was higher than reported in historical controls especially in terms of tissue fibrosis (64%) and perioperative urinary toxicity (14%).
  • CONCLUSION: A prolonged treatment with more chemotherapy courses does not improve tumor response and increases the risk of perioperative complication.
  • This treatment regimen, considering the low incidence of acute gastrointestinal toxicity, might be tested in the adjuvant setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brachytherapy / methods. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Kaplan-Meier Estimate. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Neoplasm Staging. Preoperative Care. Prospective Studies. Radiotherapy Dosage. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023568.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Low JJ, Perrin LC, Crandon AJ, Hacker NF: Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer; 2000 Jul 15;89(2):391-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Effective combination chemotherapy has improved the previously dismal prognosis for malignant ovarian germ cell tumors (MOGCT) dramatically.
  • In young patients, conservative surgery with adjuvant chemotherapy has made the preservation of fertility possible, even in patients with advanced disease.
  • METHODS: The current study is a retrospective review of 74 patients with MOGCT treated by conservative surgery, retaining the uterus and contralateral ovary to preserve ovarian function, with or without chemotherapy.
  • There were 56 International Federation of Gynecology and Obstetrics (FIGO) Stage I tumors (75.7%), 3 Stage II tumors, (4.1%), 11 Stage III tumors (14.9%), and 4 Stage IV tumors (5.4%).
  • Adjuvant chemotherapy was administered in 47 patients (63.5%).
  • Survival for patients with Stage I disease was 98.2% and that for patients with advanced disease stages was 94.4%.
  • During chemotherapy 61.7% of patients developed amenorrhea but 91.5% of these women resumed normal menstrual function on completion of chemotherapy.
  • Fourteen healthy live births were recorded in the chemotherapy group and there were no documented birth defects.
  • The majority of these patients who have received combination chemotherapy resume normal ovarian function and can expect a normal fertility rate and healthy offspring.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Cohort Studies. Cystectomy / methods. Female. Follow-Up Studies. Humans. Menstruation. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Omentum / surgery. Ovariectomy / methods. Reproduction. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10918171.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


11. Joshi SC, Sharma DN, Khurana N, Mohanta PK, Bahadur AK: Endometrial carcinoma with recurrence in the incisional scar: a case report. Int J Gynecol Cancer; 2003 Nov-Dec;13(6):901-3
MedlinePlus Health Information. consumer health - Scars.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma with recurrence in the incisional scar: a case report.
  • We report a case of papillary adenocarcinoma of uterus which developed a recurrence over the scar of surgery.
  • The patient initially underwent surgery followed by adjuvant chemoradiotherapy for her stage II disease.
  • She was disease-free until 21 months when she developed a small mass over the lower site of incisional scar.
  • Treatment of the scar recurrence consisted of palliative radiation therapy and chemotherapy.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Cicatrix / pathology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14675332.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Johann S, Mueller MD: [Follow-up after malignant tumours of the uterus (cancer of the uterine corpus / cervical cancer)]. Ther Umsch; 2008 Jun;65(6):341-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Follow-up after malignant tumours of the uterus (cancer of the uterine corpus / cervical cancer)].
  • Malignant uterine tumours can affect the corpus or the cervix.
  • The endometrial carcinoma with its different histological subtypes counts for most of the malignomas of the uterine body.
  • But the rare category of uterine sarcomas (carcinosarcomas, leiomyosarcomas as well as endometrial stromal sarcomas) also belongs to this group.
  • Cervical cancer presents an own entitity, regarding both histology and therapeutic options.
  • Endometrial cancer is the most common genital malignoma in Northern Europe and North America.
  • Histologically, the endometrial cancer can be subdivided in two groups: type I is hormonal sensitive and well differentiated, type II represents an undifferenciated aggressive tumour with poor prognosis.
  • Due to the main symptom - abnormal vaginal bleeding - endometrial cancer is detected in an early stage in about 75% of all patients.
  • First choice in therapy is stage related surgery.
  • Cervical cancer is mainly a squamous cell carcinoma and oncogenic Human Papilloma Virus (HPV) associated.
  • Surgery is only indicated up to stage IIA, advanced stages should be treated by radio-chemotherapy.
  • Intention is the detection of the curable local relapse.
  • [MeSH-major] Aftercare / methods. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Second Primary / diagnosis. Postoperative Complications / diagnosis. Uterine Cervical Neoplasms / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Evidence-Based Medicine. Female. Humans. Neoplasm Staging. Positron-Emission Tomography. Prognosis. Tomography, X-Ray Computed


13. Amin C, Hemphill B, Sittisomwong T, Malpica A, Hunt W, Verschraegen C: Characteristics of patients with endometrial stromal sarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):5145

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients with endometrial stromal sarcoma.
  • : 5145 Background: Endometrial stromal sarcoma (ESS) is by definition a low grade sarcoma, accounting for less than 1% of all tumor malignancies.
  • By comparison, the prevalence of endometrial cancer is 700 per million women.
  • Because of its rarity, the natural history of the disease and the optimal therapy have not been well established.
  • METHODS: After IRB approval, the charts of 78 patients diagnosed for the first time with ESS and treated at the University of Texas MDACC were reviewed, with emphasis on patient demographics, therapies, recurrence, and survival.
  • Endometrial FIGO stage was I in 52%, II in 6%, III in 30%, and IV in 12%.
  • The primary site was uterus in 87% and extra-uterine in 13%.
  • The median age of onset is younger than the one of endometrial cancer, but interestingly about 75% are postmenopausal at diagnosis.
  • Various treatments including hormonal therapy, chemotherapy, radiation therapy, and hysterectomy with oophorectomy have been used, and we plan to study their impact on this disease, to present at the annual meeting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016810.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kochanski JD, Roeske JC, Mell LK, Yamada SD, Mehta N, Mundt AJ: Outcome of FIGO stage I-II cervical cancer patients treated with intensity modulated pelvic radiation therapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):5027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of FIGO stage I-II cervical cancer patients treated with intensity modulated pelvic radiation therapy.
  • : 5027 Background: Intensity modulated pelvic radiation therapy (IM-PRT) is receiving increasing attention in gynecology.
  • Numerous investigators have shown that IM-PRT reduces the volume of normal tissues irradiated compared to conventional pelvic RT.
  • We present our experience using IM-PRT in stage I-II cervical cancer.
  • METHODS: Between 2/00 and 2/03, 34 stage I-II cervical cancer pts received IM-PRT.
  • 21pts (12 IB, 9 IIA-IIB) with an intact uterus underwent IM-PRT (20 received weekly cisplatin) followed by brachytherapy, and in 6, simple hysterectomy.
  • 13 stage I pts underwent surgery and received IM-PRT due to adverse features (lymphatic invasion, tumor >4 cm, positive nodes).
  • 6 also received chemotherapy and 2 brachytherapy.
  • On a contrast-enhanced CT scan, a clinical target volume was contoured consisting of the upper vagina, parametria, uterus (if present), presacral and pelvic lymph nodes, and was expanded by 1 cm creating a planning target volume (PTV).
  • This pt had stage IIB disease.
  • The 3-year PC of pts with an intact uterus and those treated adjuvantly were 91% and 100%.
  • No pt developed grade ≥ 2 gastrointestinal (GI) or genitourinary (GU) sequelae (2 had grade 1 GI and 1 grade 1 GU toxicity).
  • CONCLUSIONS: Stage I-II cervical cancer pts treated with IM-PRT have an excellent tumor control and low rate of toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015517.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Seddon BM, Scurr MR, Jones RL, Wood Z, Propert-Lewis C, A'Hern R, Whelan JS, Judson IR: Phase II study of gemcitabine and docetaxel as first-line chemotherapy in locally advanced/metastatic leiomyosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine and docetaxel as first-line chemotherapy in locally advanced/metastatic leiomyosarcoma.
  • : 10528 Background: Locally advanced/metastatic soft tissue sarcoma is invariably incurable with a poor prognosis.
  • This study aims to investigate the combination as first line treatment in patients with unresectable incurable leiomyosarcoma.
  • Patients were evaluated for response by RECIST after cycles 2, 4, 6, and 8, and three-monthly after completing treatment.
  • The study was conducted with a Simon 2-stage design, recruiting 19 patients in stage 1, and 25 patients in stage 2.
  • Eligible patients had histologically proven leiomyosarcoma of the uterus (48.9%) or other sites (51.1%) unresectable for cure, with measurable disease, no previous chemotherapy, adequate organ function, and performance status 0-2.
  • All patients had demonstrated disease progression prior to trial entry.
  • Further investigation comparing the combination with current standard therapies for leiomyosarcoma is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963919.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV, Gynecologic Oncology Research Program at Dana Farber/Partners Cancer Care, Dana Farber-Harvard Cancer Care: A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol; 2003 Nov;91(2):293-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
  • OBJECTIVES: In an effort to improve the results of primary chemotherapy for müllerian malignancies a novel chemotherapy program was piloted that delivered three sequential chemotherapy doublets.
  • After therapy, all women were clinically staged and evaluated by second-look laparoscopy/laparotomy (SLO) if clinical staging was negative for residual disease.
  • Forty-four women had either ovarian cancer or primary peritoneal carcinoma with 3 women diagnosed with fallopian tube carcinoma and 2 with papillary serous carcinoma of the uterus.
  • Eighty-four percent of patients had stage IIIc/IV tumors, with 29% having >1 cm residual disease after primary cytoreductive surgery.
  • Thirty-nine of 49 (80%) patients completed therapy.
  • A total of 283 cycles of chemotherapy were delivered with acceptable toxicities.
  • Five women were withdrawn from trial (3 for Taxol hypersensitivity, 1 for gemcitabine pulmonary hypersensitivity, and 1 for serious line infection).
  • Thirty-nine women completed all cycles of treatment.
  • CONCLUSIONS: Treatment with this sequential doublet regimen is feasible with a 38% pathologic CR rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Deoxycytidine / analogs & derivatives. Genital Neoplasms, Female / drug therapy. Mixed Tumor, Mullerian / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Middle Aged. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Topotecan / administration & dosage. Topotecan / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599858.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


17. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC: Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol; 2006 Aug;108(2):361-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
  • OBJECTIVE: To analyze the clinical behavior of patients with stage II-IV low-grade serous carcinoma of the ovary seen at our institution who underwent primary surgery followed by platinum-based chemotherapy.
  • METHODS: Patients with stage II-IV low-grade serous carcinoma of the ovary from 1978 to 2003 were identified using existing databases.
  • ; 90% had stage III disease.
  • Preoperative serum CA 125 was elevated in 86% of patients.
  • The most common sites of extraovarian disease were omentum, fallopian tubes, pelvic peritoneum, and uterus.
  • Response rate to platinum-based chemotherapy in 10 evaluable patients (15% of patients with gross residual disease) was 80%, and 42 patients underwent second-look surgery: microscopically negative findings, 2 (5%); microscopically positive disease, 13 (33%); macroscopically positive disease, 24 (62%); and insufficient information, 3 (7%).
  • Median progression-free survival and overall survival times were 19.5 and 81.8 months.
  • Persistent disease after primary chemotherapy was the only factor associated with shorter overall survival time (hazard ratio 3.46, 95% confidence interval 2.00-5.97, P<.001).
  • CONCLUSION: Metastatic low-grade serous carcinoma of the ovary is characterized by young age at diagnosis and prolonged overall survival.
  • [MeSH-major] Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / therapy. Ovarian Neoplasms / mortality. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Analysis. Texas / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880307.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ: Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys; 2004 Mar 1;58(3):786-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.
  • PURPOSE: To determine the survival outcomes, prognostic factors, and patterns of failure in patients with malignant mixed Müllerian tumor (MMMT) of the uterus.
  • METHODS AND MATERIALS: Between 1954 and 1998, 300 patients with clinical Stage I-III MMMT of the uterus were treated with curative intent at The University of Texas M. D.
  • Anderson Cancer Center.
  • Their hospital records were reviewed to obtain patient and tumor characteristics; details of surgery, radiotherapy (RT), and chemotherapy; and long-term outcome.
  • Forty-eight patients received adjuvant chemotherapy.
  • Women who were postmenopausal or had a history of prior pelvic RT, pain at presentation, clinical Stage II-III disease, uterine enlargement (>/=12 weeks), or an abnormal Papanicolaou smear finding had a significantly poorer prognosis than the other patients in the series.
  • Of the 273 patients who underwent surgery, those who had positive abdominal washings, uterine length >10 cm, or extrauterine spread of disease to the cervix, adnexa, or peritoneum had a significantly worse prognosis than the other patients.
  • Factors found on multivariate analysis to have an independent adverse influence on cause-specific survival included postmenopausal status (p = 0.0007, relative risk [RR] 3.3), uterine length >10 cm (p = 0.0001, RR 2.2), cervical involvement (p = 0.002, RR 1.8), and peritoneal involvement (p = 0.0001, RR 4.3).
  • However, patients treated with pelvic RT had a longer mean time to any distant relapse (17.3 vs. 7.0 months, p = 0.001) than patients treated with surgery alone.
  • The use of adjuvant chemotherapy did not correlate with the survival rate or rate of distant metastasis.
  • As more effective systemic chemotherapy is developed to control microscopic distant disease, the role of RT in controlling locoregional disease in the pelvis and abdomen may become more important.
  • Future research should consider programs that integrate surgery, RT, and chemotherapy to maximize the probability of cure.
  • [MeSH-major] Mixed Tumor, Malignant / mortality. Mixed Tumor, Mullerian / mortality. Uterine Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Postmenopause. Postoperative Complications. Prognosis. Radiation Injuries / pathology. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14967435.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Coukos G, Rubin SC: Early ovarian cancer. Curr Treat Options Oncol; 2000 Jun;1(2):129-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early ovarian cancer.
  • Epithelial ovarian cancer may appear to be confined to the ovaries or pelvis in approximately one-third of patients at exploration, but up to 30% of them will be upstaged following surgical staging.
  • Substage and histotype are the most important prognostic factors that determine the need for adjuvant treatment.
  • Patients with stage Ia or Ib and well-differentiated (other than clear cell) tumors do not require adjuvant treatment.
  • Patients with stage Ia or Ib grade 3 or clear cell histology, as well as any stage Ic and II disease, are at high risk for recurrence.
  • Platinum-based chemotherapy is the mainstay of treatment.
  • Four to six courses are probably adequate, although grade 3 tumors may require further treatment.
  • Preservation of the uterus and the uninvolved contralateral ovary is a viable option in young women with unilateral early disease.
  • [MeSH-major] Ovarian Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Survival Rate. Urogenital Surgical Procedures

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1998 Jan;68(1):47-53 [9454660.001]
  • [Cites] Gynecol Oncol. 1998 Oct;71(1):19-28 [9784314.001]
  • [Cites] Ann Oncol. 1995 Nov;6(9):887-93 [8624291.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3408-15 [9363873.001]
  • [Cites] Obstet Gynecol. 1993 Jul;82(1):139-42 [8515914.001]
  • [Cites] Am J Obstet Gynecol. 1993 Jul;169(1):40-52 [8333474.001]
  • [Cites] Gynecol Oncol. 1999 Jul;74(1):128-9 [10385564.001]
  • [Cites] N Engl J Med. 1999 Feb 4;340(5):351-7 [9929525.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1997 Apr;72(2):181-90 [9134399.001]
  • [Cites] Semin Oncol. 1998 Oct;25(5):522-4 [9783591.001]
  • [Cites] Obstet Gynecol. 1985 Apr;65(4):568-72 [3982731.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):526-30 [9761124.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(12):727-33 [8104946.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Sep;104(9):1030-5 [9307530.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):288-91 [10053097.001]
  • [Cites] Gynecol Oncol. 1995 Sep;58(3):301-6 [7672696.001]
  • [Cites] Surg Gynecol Obstet. 1989 Sep;169(3):226-32 [2772792.001]
  • [Cites] N Engl J Med. 1990 Apr 12;322(15):1021-7 [2181310.001]
  • [Cites] Gynecol Oncol. 1999 Dec;75(3):387-90 [10600294.001]
  • [Cites] Semin Oncol. 1995 Dec;22(6 Suppl 15):1-6 [8643963.001]
  • [Cites] J Natl Cancer Inst Monogr. 1993;(15):25-37 [7912527.001]
  • [Cites] Compr Ther. 1999 Mar;25(3):144-50 [10200903.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):25-33 [7557611.001]
  • (PMID = 12057050.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


20. Dem A, Kasse AA, Diop M, Cisse B, Toure P: [Epidemiological factors, treatment and prognosis of uterine sarcomas: 14 cases at the Cancer Institute of Dakar]. Dakar Med; 2000;45(1):85-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiological factors, treatment and prognosis of uterine sarcomas: 14 cases at the Cancer Institute of Dakar].
  • [Transliterated title] Etude des facteurs épidémiologiques, du traitement et du prognostic des sarcomes de l'utérus: à propos de 14 cas colligés à l'Institut du Cancer de Dakar.
  • The study of uterus sarcoma took in interest because these tumors were unrecognized and sat nowadays many questions.
  • The purpose of this study is to review the epidemiological factors, the problems of treatment and prognostic of uterus sarcoma.
  • It's a retrospective study of 14 sarcomas of uterus reported from 1959 to 1997.
  • The clinical investigation found according the FIGO staging: 6 stage I (42.6%), 4 stage II (28.4%), 1 stage III (7.1%) and 3 stage IV (21.4%).
  • Surgery was the principal treatment: it was alone on 3 cases (24.9%), associated with chemotherapy on 8 cases (66.8%) and one patient had an association surgery, chemotherapy and radiotherapy.
  • The global survival was 21.4% at 2 years and all the patients were dead at 5 years and it seemed that it would be better when the patients were treated by radical surgery associated with chemotherapy and radiotherapy.
  • [MeSH-major] Sarcoma / epidemiology. Sarcoma / therapy. Uterine Neoplasms / epidemiology. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Age Distribution. Aged. Biopsy. Cancer Care Facilities. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Postmenopause. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Senegal / epidemiology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666799.001).
  • [ISSN] 0049-1101
  • [Journal-full-title] Dakar médical
  • [ISO-abbreviation] Dakar Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Senegal
  •  go-up   go-down


21. Manolitsas TP, Wain GV, Williams KE, Freidlander M, Hacker NF: Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus. Cancer; 2001 Apr 15;91(8):1437-43
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus.
  • BACKGROUND: The role of adjuvant therapy in the management of patients with malignant mixed Müllerian tumors (MMMT) of the uterus has not been defined.
  • The outcome of planned multimodality therapy for patients with apparent early stage disease was assessed.
  • METHODS: A pilot study was performed on 38 patients with clinical Stage I or II MMMTs of the uterus who were offered treatment according to a standard protocol.
  • The protocol consisted of removal of the uterus, fallopian tubes, and ovaries and surgical staging followed by tailored radiation therapy and chemotherapy, consisting of cisplatin and epirubicin.
  • The mean time to death from disease was 26 months (range, 7-87 months).
  • The survival rate for those patients who completed treatment according to the multimodality protocol was 95% (20 of 21 patients), with a disease free survival rate of 90% (19 of 21 patients).
  • The overall survival of patients who did not receive the recommended treatment protocol for various reasons was 47% (8 of 17 patients).
  • An analysis of survival curves demonstrated that there was a significant survival advantage for those patients who completed the treatment according to the multimodality protocol (P = 0.01).
  • CONCLUSIONS: In this pilot study, patients with clinical Stage I or II MMMTs who underwent surgical staging and aggressive adjuvant radiation and chemotherapy had an excellent survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mixed Tumor, Mullerian / radiotherapy. Mixed Tumor, Mullerian / surgery. Uterine Neoplasms / radiotherapy. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Epirubicin / administration & dosage. Female. Humans. Hysterectomy. Middle Aged. Ovariectomy. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11301390.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA: Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol; 2003 Dec 1;21(23):4314-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
  • PURPOSE: We determined the risk of breast cancer and tumor characteristics among current postmenopausal hormone therapy users compared with nonusers, by duration of use.
  • We calculated the relative risk (RR) of breast cancer (invasive or ductal carcinoma-in-situ) and type of breast cancer within 12 months of postmenopausal therapy use among current hormone users with a uterus (proxy for estrogen and progestin use) and without a uterus (proxy for estrogen use), compared with nonusers.
  • RESULTS: Compared with nonusers, women using estrogen and progestin for >/= 5 years were at increased risk of breast tumors of stage 0 or I (RR, 1.51; 95% CI, 1.37 to 1.66), stage II or higher (RR, 1.46; 95% CI, 1.30 to 1.63), size </= 20 mm (RR, 1.59; 95% CI, 1.43 to 1.76), size greater than 20 mm (RR, 1.24; 95% CI, 1.09 to 1.42), grade 1 or 2 (RR, 1.60; 95% CI, 1.44 to 1.77), grade 3 or 4 (RR, 1.54; 95% CI, 1.37 to 1.73), and estrogen receptor-positive (RR, 1.72; 95% CI, 1.55 to 1.90).
  • Estrogen-only users were slightly more likely to have estrogen receptor-positive breast cancer compared with nonusers (RR, 1.14; 95% CI, 1.06 to 1.23).
  • CONCLUSION: Use of estrogen and progestin postmenopausal hormone therapy for five years or more increased the likelihood of developing breast cancer, including both tumors with favorable prognostic features and tumors with unfavorable prognostic features.
  • [MeSH-major] Breast Neoplasms / epidemiology. Estrogen Replacement Therapy / adverse effects. Estrogens / adverse effects. Postmenopause / drug effects. Progestins / adverse effects
  • [MeSH-minor] Aged. Carcinoma in Situ / diagnosis. Carcinoma in Situ / epidemiology. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / epidemiology. Drug Combinations. Female. Humans. Mass Screening. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Prospective Studies. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14645420.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01CA63731; United States / NCI NIH HHS / CA / U01CA63736; United States / NCI NIH HHS / CA / U01CA63740; United States / NCI NIH HHS / CA / U01CA69976; United States / NCI NIH HHS / CA / U01CA70013; United States / NCI NIH HHS / CA / U01CA70040; United States / NCI NIH HHS / CA / U01CA86076; United States / NCI NIH HHS / CA / U01CA86082
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Estrogens; 0 / Progestins
  •  go-up   go-down


23. Silva EG, Deavers MT, Bodurka DC, Malpica A: Uterine epithelioid leiomyosarcomas with clear cells: reactivity with HMB-45 and the concept of PEComa. Am J Surg Pathol; 2004 Feb;28(2):244-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine epithelioid leiomyosarcomas with clear cells: reactivity with HMB-45 and the concept of PEComa.
  • In this study, we investigated HMB-45 expression in epithelioid uterine leiomyosarcomas with clear cell areas.
  • Presenting symptoms were uterine bleeding (three), abdominal pain (one), and a pelvic mass (one).
  • One patient had stage II disease, one stage III, and three stage IV.
  • Two received radiotherapy, and three were also treated with chemotherapy.
  • Three patients died of disease at 9, 30, and 32 months; one patient is alive with progressive disease at 6 months, and one patient (stage II disease) is alive with no evidence of disease at 8 months.
  • Unequivocal uterine epithelioid leiomyosarcomas may have clear cells positive for HMB-45.
  • These tumors might belong to the group of lesion designated as PEComas; however, it is advisable to designate them as uterine leiomyosarcomas.
  • In uterine smooth muscle tumors, some epithelioid cells most likely undergo clear cell changes and become positive for HMB-45.
  • It would be advisable to perform this stain in all epithelioid smooth muscle tumors of the uterus.
  • [MeSH-major] Leiomyosarcoma / metabolism. Leiomyosarcoma / pathology. Neoplasm Proteins / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15043315.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


24. Li YF, Li MD, Wu QL, Liu FY, Li JD, Zou JL, Huang YW: [Clinical analysis of 57 patients with ovarian dysgerminoma]. Ai Zheng; 2002 Jan;21(1):79-82
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: The data of 57 patients with pure Ovarian Dysgerminoma were analyzed retrospectively, who were admitted to Cancer Center, Sun Yat-sen University of Medical Sciences from January 1, 1964 to December 31, 2000.
  • Twenty-six patients had stage Idiseases, 8 stage II, 9 stage III, 1 stage IV and 13 recurrent and persistent diseases.
  • The uterus was involved in 41.2% patients with stage II-III diseases.
  • Combined modality was given to 52 cases and single-method treatment 5 cases.
  • The overall 5-year and 10-year survival rate for stage I-IV was 80.1% and 70.0% respectively.
  • The 5-year survival rate for stage I was 100%, stage II 55.2%, stage III 55.6%, stage IV 0% and recurrent and persistent diseases 72.7%.
  • In the group of stage I, 12 patients received adnexectomy and 14 patients underwent hysterectomy and adnex removal, there was no significant difference between the 5-year and 10-year survival rate (all 100%) (P < 0.05).
  • Of 23 patients in stage I group to whom only chemotherapy were given after operation, 19 cases received 3 or more courses and were well being without recurrence; four patients received only one course and one of them recurred 21 months after operation.
  • In the group of stage II and III cases the 5-year survival rate was 86.7% for those whose chemotherapy courses were > or = 4 and 25.0% for patients who received less than 4 courses of chemotherapy (P < 0.05).
  • CONCLUSIONS: The prognosis of ovarian dysgerminoma is closely related to disease stage and modality of treatment.
  • [MeSH-major] Dysgerminoma / therapy. Ovarian Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12500404.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Ma SK, Zhang HT, Sun YC, Wu LY: [Synchronous primary cancers of the endometrium and ovary: review of 43 cases]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):690-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment methods, and prognosis of synchronous primary cancers of the endometrium and ovary.
  • METHODS: The clinical data of 43 patients with synchronous primary cancers of the endometrium and ovary were retrospectively reviewed.
  • The most common symptoms were abnormal vaginal bleeding (69.8%) and abdominal or pelvic pain (44.2%).Pelvic masses were found in 39.5% of the patients and enlarged corpus in 27.9% at physical examination, while pelvic masses were found in 67.4% of the 43 patients (29 cases) and thickening or abnormal endometrium in 23.3% (10 cases) during ultrasound examination.
  • Of 25 patients examined by CT/MRI, pelvic masses were found in 13 cases and enlarged uterus in 11 cases.
  • All 15 patients who underwent endometrial biopsies were proven to have endometrial carcinomas.
  • FIGO stages of endometrial carcinomas: IA 18 cases, IB 20 cases, IC 2 cases, IIA 3 cases; Stages of ovarian carcinomas: IA 19 cases, IB 4 cases, IC 7 cases, II 4 cases, III C 9 cases.
  • Twenty-four patients (55.8%) were in stage I both endometrial and ovarian carcinomas.
  • Thirty-eight of the 43 patients (88.4%) had a pathologically proven endometrial adenocarcinoma.
  • Postoperatively, 26 patients (60.5%) received adjuvant chemotherapy alone, 12 had chemotherapy plus radiotherapy, only one patient had radiation alone and the remaining 4 cases received no adjuvant treatment.
  • The 3-year and 5-year survival rates of patients with early stage disease were better than those of the other patients (93.3%, 93.3% vs. 69.7%, 36.7%).
  • Recurrence developed in 15 patients (34.9%).
  • It was showed by univariate analysis that lower CA125 level, early FIGO stage, and adjuvant chemotherapy plus radiotherapy significantly and positively affect the 5-year survival rates, while only early FIGO stage and chemotherapy plus radiotherapy were revealed by multivariate analysis as independent prognostic factors.
  • CONCLUSION: Synchronous primary cancers of the endometrium and ovary are different from either primary endometrial carcinoma or ovarian cancer, while it can usually be detected in early stage and with a good prognosis.
  • Surgical treatment alone may be enough for early stage patients.
  • Chemotherapy plus radiotherapy may be necessary for advanced stage patients.
  • [MeSH-major] Carcinoma, Endometrioid. Endometrial Neoplasms. Hysterectomy / methods. Neoplasms, Multiple Primary. Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Proteins / metabolism. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173912.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


26. Gonzalez Bosquet J, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, Keeney GL: The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol; 2010 Mar;116(3):419-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of multi-modal therapy on survival for uterine carcinosarcomas.
  • OBJECTIVES: To investigate treatment outcomes of patients with carcinosarcoma of the uterus and to identify parameters predictive of survival.
  • Secondary objectives included (a) the assessment of treatment failures as a function of histologic subtypes and (b) the impact of the new FIGO staging classification system.
  • METHODS: This is a retrospective outcomes analysis of 121 patients diagnosed with primary carcinosarcoma of the uterus.
  • Clinical, surgical and pathological data were reviewed and patients were classified according to the new 2009 FIGO staging system for endometrial carcinoma.
  • RESULTS: In the multivariate analyses for disease-specific survival (DSS) and disease-free survival (DFS), the only independent factors were FIGO stage, adjuvant chemotherapy after surgery and the presence of clear cell histology in the tumor.
  • The 5-year DSS for stages I-II, III and IV was 59%, 22% and 9%, respectively.
  • The administration of platin-based chemotherapy provided a significant benefit with regard to both DFS (OR=0.28; p=0.001) and DSS (OR=0.35; p=0.01).
  • CONCLUSIONS: This highly aggressive uterine malignancy warrants comprehensive surgical staging to assess tumor dissemination followed by systemic therapy in patients with both early and advanced stage disease.
  • [MeSH-major] Carcinosarcoma / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19896181.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, Reyes L, Posternak R, Morosoli G, Verde ML, Rosales R: Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther; 2004 May;15(5):421-31
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus.
  • Human papillomavirus (HPV) infection is associated with cervical cancer.
  • Cervical cancer is a serious problem in developing countries because it is usually not detected at an early stage.
  • In a phase I/II clinical trial, we evaluated the potential use of the MVA E2 recombinant vaccinia virus to treat cervical intraepithelial neoplasia CIN 1, CIN 2, and CIN 3 lesions associated with human papillomavirus (HPV) infection.
  • Thirty-six women received the recombinant virus vaccine at a total of 10(7) MVA E2 virus particles injected directly into the uterus once every week over a 6-week period.
  • The type of immune response after MVA E2 injection was determined by measuring antibody titers against MVA E2 virus and the E2 protein, and by the presence of cytotoxic activity against cancer cells bearing papillomavirus DNA.
  • Thirty-four of 36 patients showed complete elimination of precancerous lesions after treatment with the MVA E2 vaccine.
  • Three other patients presented isolated koilocytes after treatment with MVA E2.
  • Colposcopy revealed no lesions in 85% of patients, and only small aceto-white spots were detected in 15% of patients after treatment with MVA E2.
  • All patients developed antibodies against the MVA E2 vaccine, and vaccination generated a specific cytotoxic response against HPV-transformed cells.
  • Furthermore, 50% of patients showed no evidence of papillomavirus after treatment with MVA E2, while the remaining 50% showed persistence of HPV DNA, but at approximately only 10% of the original viral load.
  • Cryosurgery eliminated the lesions of CIN 1 in all patients, but patients so treated did not develop cytotoxic activity against cancer cells.
  • These results show that therapeutic vaccination with MVA E2 vaccine is an excellent prospective means for stimulating the immune system and causing the regression of precancerous CIN 1, CIN 2, and CIN 3 lesions when the vaccine is given locally.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Uterine Cervical Neoplasms / prevention & control. Vaccines, DNA / therapeutic use. Vaccinia virus / immunology
  • [MeSH-minor] Adult. Cell Transformation, Viral. Colposcopy. Cytotoxicity Tests, Immunologic. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Papillomaviridae / immunology. Papillomavirus Infections / blood. Patient Selection. Treatment Outcome. Viral Load

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15144573.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vaccines, DNA
  •  go-up   go-down


28. Hu Y, Feng FY, Zhang P, Zhou LQ, Zhang WH, Wang QL: [Primary non-Hodgkin lymphoma in the female genital system: a report of 28 cases]. Zhonghua Zhong Liu Za Zhi; 2003 Sep;25(5):486-9
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the clinical characteristics, results of treatment, and prognostic factors of patients diagnosed as having primary female genital system lymphoma (PFGSL).
  • METHODS: Twenty-eight cases of PFGSL were retrospectively surveyed and the clinical data of the patients were analyzed by statistic software package of SPSS10.0 for relation between clinical stage, grade, pathologic feature, treatment and prognosis.
  • It mainly involved cervix uterus, ovary and vulva.
  • The disease had a broad range of pathologic type and 20 patients were diagnosed as suffering from B-cell by immunophenotyping, 4 patients were diagnosed as T-cell and 4 patients lesions were indefinite.
  • The Ann Arbor stage included: Stage I(E)-12 pts (42.86%), Stage II(E)-3 pts (10.7%), Stage III(E)-1 pts (3.6%) and Stage IV-12 pts (42.86%).
  • Most patients were given comprehensive treatment without any mode showing significant advantage over the others in survival (P = 0.2554), The involved organs, Ann Arbor stage, IWF and also IPI were significant prognostic factors for survival, CONCLUSION: The management of PFGSL should be based on comprehensive treatment including chemotherapy as the chief means.
  • The significant prognostic factors of survival is Ann Arbor stage, IPI, IWF and the kind of involved organs.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14575576.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. Nakamura S, Kato M, Ichimura K, Yatabe Y, Kagami Y, Suzuki R, Taji H, Kondo E, Asakura S, Kojima M, Murakami S, Yamao K, Tsuzuki T, Adachi GK, Miwa A, Yoshidai T: Peripheral T/natural killer-cell lymphoma involving the female genital tract: a clinicopathologic study of 5 cases. Int J Hematol; 2001 Jan;73(1):108-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They include 2 from the uterus and 1 each from ovary, uterus and ovary, and vagina, and were detected between 1996 and 2000.
  • One case was stage I disease, 2 were stage II, and 2 were stage IV.
  • Three were diagnosed as nasal type T/NK-cell lymphoma, 1 as anaplastic large-cell lymphoma (anaplastic lymphoma kinase [ALK]-positive), and 1 as unspecified PTCL of cytotoxic phenotype, according to the forthcoming World Health Organization classification.
  • Four of 5 patients received laparotomy and chemotherapy.
  • Four patients (in stages II and IV) died of disease within 16 months of the initial diagnosis, whereas only 1 patient (in stage I) is alive without disease at 39 months of follow-up.
  • Our experience in this series provided clinically relevant information on diagnosis, treatment, and outcome for extremely rare tumors of the FGT.
  • [MeSH-minor] Adult. Female. Humans. Immunophenotyping. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1988 Aug;90(2):156-62 [3293419.001]
  • [Cites] Am J Obstet Gynecol. 1982 Aug 15;143(8):870-5 [7102762.001]
  • [Cites] Obstet Gynecol. 1974 Nov;44(5):735-48 [4528975.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1184-200 [10524519.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1198-205 [8635144.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):651-4 [10203609.001]
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):567-78 [10609794.001]
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):619-22 [10609801.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Pathol Int. 1997 Jan;47(1):38-53 [9051691.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1236-41 [9331298.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1420-32 [9414185.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):284-96 [7532919.001]
  • [Cites] Lab Invest. 1992 Oct;67(4):457-64 [1331609.001]
  • [Cites] Mod Pathol. 1999 Feb;12(2):109-15 [10071336.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1954-60 [7655022.001]
  • [Cites] J Obstet Gynaecol Res. 1998 Jun;24(3):183-7 [9714988.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Blood. 1994 Apr 15;83(8):2255-60 [8161791.001]
  • [Cites] J Surg Oncol. 1986 Oct;33(2):126-8 [3531726.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):128-30 [1967431.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Immunol Today. 2000 Apr;21(4):160-3 [10740235.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):719-25 [10800991.001]
  • [Cites] Ultrastruct Pathol. 1990 May-Jun;14(3):247-52 [2192488.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1933-43 [6627208.001]
  • [Cites] Obstet Gynecol. 1984 Sep;64(3 Suppl):93S-94S [6472755.001]
  • [Cites] Jpn J Clin Oncol. 1989 Jun;19(2):163-6 [2733170.001]
  • [Cites] Cancer. 1974 Aug;34(2):397-407 [4853080.001]
  • [Cites] Br J Obstet Gynaecol. 1988 Apr;95(4):386-90 [3382612.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):1893-900 [9176382.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3785-91 [7524749.001]
  • [Cites] Medicine (Baltimore). 1961 Feb;40:31-84 [13743408.001]
  • [Cites] Am J Surg Pathol. 1993 Feb;17(2):154-70 [8422111.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1723-31 [9473239.001]
  • [Cites] Pathol Annu. 1991;26 Pt 1:227-63 [2014141.001]
  • [Cites] Immunol Today. 1991 Nov;12(11):415-9 [1786074.001]
  • [Cites] Hum Pathol. 1990 Oct;21(10):1041-50 [2210727.001]
  • [Cites] Hematol Oncol. 1990 Sep-Oct;8(5):295-9 [1701156.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2530-45 [6585265.001]
  • (PMID = 11372745.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


30. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH: Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol; 2008 Sep;110(3):345-53
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes.
  • OBJECTIVE: Younger patients with invasive epithelial ovarian cancer (EOC) frequently want to preserve their fertility, but the role of fertility-sparing surgery in EOC has not been well defined.
  • METHODS: Records of 62 patients with invasive EOC who underwent fertility-sparing surgery, defined as the preservation of ovarian tissue in one or both adnexa and the uterus, between May 1990 and October 2006, were retrospectively reviewed.
  • RESULTS: Of the 62 EOCs, 36 were stage IA, 2 were stage IB, 21 were stage IC, and 1 each was stage IIB, IIIA, and IIIC; 48 were grade I, 5 were grade II, and 9 were grade III.
  • Forty-eight patients received platinum-based adjuvant chemotherapy (mean 4.6 cycles, range 1-9 cycles).
  • Patients with stage >IC (p=0.0014) or grade III (p=0.0002) tumors had significantly poorer survival.
  • CONCLUSION: Fertility-sparing surgery can be considered in young patients with stages IA-C and grades I-II EOCs who desire to preserve their fertility.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Disease-Free Survival. Female. Gynecologic Surgical Procedures / adverse effects. Gynecologic Surgical Procedures / methods. Humans. Neoplasm Invasiveness. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2009 Mar;112(3):673-4; author reply 674 [18986689.001]
  • (PMID = 18586310.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Kreĭnina IuM, Titova VA, Shipilova AN, Povarova EV, Shevchenko LN: [Improvement of postoperative radiotherapy in the complex treatment of stage II-III cervical cancer]. Vopr Onkol; 2006;52(1):83-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improvement of postoperative radiotherapy in the complex treatment of stage II-III cervical cancer].
  • Clinical data on the management of squamous-cell cervical carcinoma stage II-III FIGO are presented.
  • At stage I, treatment included neoadjuvant polychemotherapy (NACT)--cisplatin 100 mg/m2, carboplatin 450 mg/m2 in conjunction with 5-FU 250 mg/m2 or paclitaxel 135 mg/m2.
  • According to protocol, two identical courses of NACT were given, at 21-28 day interval, followed by extended extirpation of the uterus (Wertheim).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Hysterectomy. Neoadjuvant Therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant / adverse effects. Survival Analysis. Treatment Outcome


32. Rosen AC, Ausch C, Klein M, Graf AH, Metzenbauer M, Philipp K, Reiner A: p53 expression in fallopian tube carcinomas. Cancer Lett; 2000 Aug 1;156(1):1-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-three women treated for primary carcinoma of the fallopian tube (PFTC) from 1980-1995 were retrospectively analyzed to study the impact of p53 expression on survival in primary carcinoma of the fallopian tube.
  • Twenty-four (38%) patients were FIGO stage I, 11 (18%) stage II, 19 (30%) stage III and nine (14%) stage IV.
  • In 56 (89%) women, surgery involved removal of the uterus, the adnexa, and/or the omentum or lymph nodes.
  • Adjuvant therapy consisted of either chemotherapy (n: 31; 49%) or irradiation (n: 21; 33%).
  • For stages I+II and III+IV the 5-year survival rate was 59 and 19%, respectively (P<0.00001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10840153.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down






Advertisement